News und Analysen
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
5 Things Pfizer's Management Just Said That You Don't Want to Miss
Forget Pfizer's (NYSE: PFE) third-quarter earnings announcement. The real story lies in what the company's top executives said afterward.The big pharma company reported its third-quarter results....
Align Technologies Keeps Rising; Twitter Finally Has a Good Week
In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Motley Fool Pro and Options' Jeff Fischer first reflect on the....
Align Technologies Keeps Rising; Twitter Finally Has a Good Week
In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Motley Fool Pro and Options' Jeff Fischer first reflect on the....
Align Technologies Keeps Rising; Twitter Finally Has a Good Week
In this segment of the Motley Fool Money podcast, host Chris Hill, Million Dollar Portfolio's Jason Moser and Matt Argersinger, and Motley Fool Pro and Options' Jeff Fischer first reflect on the....
Why ImmunoGen, Inc. Got Burned into ASH Today
ImmunoGen (NASDAQ: IMGN) closed down 12.6% on Wednesday, following the release of abstracts for the American Society of Hematology (ASH) meeting next month.The data covers a pair of ImmunoGen's....
Here's Why It's Oca-Liftoff for Intercept Pharmaceuticals Inc.
Shares of Intercept Pharmaceuticals (NASDAQ: ICPT), a small-cap biotech company focused on the development of drugs to treat an assortment of liver diseases, vaulted higher by as much as 10% on....
BioMarin Pharmaceutical Inc. on Target for Its 15% Revenue Growth Goal
It was a solid third quarter for BioMarin Pharmaceutical (NASDAQ: BMRN) as the biotech keeps plugging along, increasing sales of its orphan drugs while making progress on its pipeline drug....
Why Surgery Partners Inc. Is Plunging Today
In response to the company preannouncing disappointing earnings, shares of Surgery Partners (NASDAQ: SGRY), a business focused on surgical services, fell 15% as of 3:30 p.m. EDT on....
What's Causing Adamas Pharmaceuticals to Spike Higher Today
After a leading hedge fund reported it bought shares last month and in the wake of industry watcher upgrades, shares in Adamas Pharmaceuticals (NASDAQ: ADMS) rallied more than 10% higher earlier....
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Pfizer Inc. (PFE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Pfizer Inc. (NYSE: PFE)Q3 2017 Earnings Conference CallOct. 31, 2017, 8:00 a.m. EDTOperatorContinue readingSource: Fool.com
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially....
Why bluebird bio Inc. Jumped Higher Today
Shares of biotech bluebird bio (NASDAQ: BLUE) are up 7.3% at 12:24 p.m. EDT, having been up as much as 16.3% today, after the company disclosed data in its abstracts for the American Society of....
3 Worst Performing Stocks in October
Halloween has come and gone, but some stocks have been more tricks than treats. As good as October may have been for a lot of investors, some stocks got totally crushed last month.Trivago (NASDAQ:....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL)....
Up in Smoke: This Marijuana Stock Imploded Last Week
Few industries have put a wider smile on investors' faces this year than marijuana. As recently as June, the average marijuana stock was higher by more than 330% over the trailing 12-month period,....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
If I Could Buy Only 1 Stock, This Would Be It
What are the top three things you like in a stock? For me, the answer is pretty easy: I like growth most of all. Everyone wants their stocks to appreciate in value.Second, I like dividends. The....
Masimo Corporation's Mighty Momentum Continues in 3rd Quarter
Things looked so great for Masimo Corporation (NASDAQ: MASI) when it reported results from the second quarter in August that the company upped its full-year guidance. Revenue and earnings soared,....
The Clear Reason Why Stemline Therapeutics Inc. Skyrocketed as Much as 33%
Shares of Stemline Therapeutics (NASDAQ: STML), a small-cap clinical-stage biotechnology company with a focus on developing medicines to treat cancer, skyrocketed as much as 33% during Tuesday's....
BASTIDE : Honoraires des controleurs légaux (exercice clos au 30 juin 2017)
MONTANT DES HONORAIRES DES COMMISSAIRES AUX COMPTES
VERSES AU 30 JUIN 2017
Conformément à l'article 221-1-2 du Règlement général de l'Autorité des Marchés financiers
En euros hors....
Ionis Down Big on Analyst Miss
This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize,....